(Q35918842)

English

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

scientific article published in December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 reference

based on heuristic

inferred from title

author name string

Barbara Romanowski

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Tino F Schwarz

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Linda M Ferguson

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Klaus Peters

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Marc Dionne

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Karin Schulze

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Brian Ramjattan

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Peter Hillemanns

8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Grégory Catteau

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Kurt Dobbelaere

10

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Anne Schuind

11

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Dominique Descamps

12

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

publication date

1 December 2011

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

12

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1374-1386

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338934

27 July 2018

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338934

27 July 2018

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338934

27 July 2018

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338934

27 July 2018

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338934

27 July 2018

Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338934

27 July 2018

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338934

27 July 2018

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338934

27 July 2018

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

1 reference

https://api.crossref.org/works/10.4161%2FHV.7.12.18322

21 January 2018

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

1 reference

https://api.crossref.org/works/10.4161%2FHV.7.12.18322

21 January 2018

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.4161%2FHV.7.12.18322

21 January 2018

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.4161%2FHV.7.12.18322

21 January 2018

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

1 reference

https://api.crossref.org/works/10.4161%2FHV.7.12.18322

21 January 2018

A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory.

1 reference

https://api.crossref.org/works/10.4161%2FHV.7.12.18322

21 January 2018

Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation

1 reference

https://api.crossref.org/works/10.4161%2FHV.7.12.18322

21 January 2018

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc

1 reference

https://api.crossref.org/works/10.4161%2FHV.7.12.18322

21 January 2018

National and state vaccination coverage among adolescents aged 13 through 17 years--United States, 2010.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338934

24 September 2018

Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus

1 reference

https://api.crossref.org/works/10.4161%2FHV.7.12.18322

21 January 2018

Identifiers

10.4161/HV.7.12.18322

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35918842&oldid=1522405790"